Zhiyi Biotechnology

Executive Summary

Zhiyi Biotechnology is a Shanghai-based biologics company specializing in the development and manufacturing of biosimilar and novel antibody therapies. Founded in 2009, the company leverages advanced cell line development and bioprocessing technologies to produce high-quality, affordable biologic medicines, initially targeting the Chinese market. With a focus on oncology and immunology, Zhiyi has advanced multiple candidates to phase 3 clinical trials, positioning itself as a key player in China's growing biosimilar sector. The company's strategy aligns with the Chinese government's push to increase access to cost-effective biologics through the National Reimbursement Drug List (NRDL). As a private company, Zhiyi is progressing toward commercialization with several late-stage biosimilars, including potential copies of major reference products such as bevacizumab and trastuzumab. The company's novel antibody pipeline, though less disclosed, may include preclinical or early clinical candidates targeting immune checkpoints. With a strong manufacturing base and expertise in bioprocessing, Zhiyi is well-positioned to capture market share as biosimilar competition intensifies in China. Key upcoming milestones include regulatory decisions and clinical data readouts that could significantly impact the company's valuation and partnership opportunities.

Upcoming Catalysts (preview)

• Q3 2026NMPA Approval of Bevacizumab Biosimilar75% success
• Q4 2026Phase 3 Data Readout for Trastuzumab Biosimilar80% success
• TBDStrategic Partnership for Commercialization in China60% success